370 related articles for article (PubMed ID: 22144891)
1. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants.
Lee CY; Kam YW; Fric J; Malleret B; Koh EG; Prakash C; Huang W; Lee WW; Lin C; Lin RT; Renia L; Wang CI; Ng LF; Warter L
PLoS Pathog; 2011 Dec; 7(12):e1002390. PubMed ID: 22144891
[TBL] [Abstract][Full Text] [Related]
2. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis.
Lam S; Nyo M; Phuektes P; Yew CW; Tan YJ; Chu JJ
MAbs; 2015; 7(6):1178-94. PubMed ID: 26305993
[TBL] [Abstract][Full Text] [Related]
3. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency.
Warter L; Lee CY; Thiagarajan R; Grandadam M; Lebecque S; Lin RT; Bertin-Maghit S; Ng LF; Abastado JP; Desprès P; Wang CI; Nardin A
J Immunol; 2011 Mar; 186(5):3258-64. PubMed ID: 21278338
[TBL] [Abstract][Full Text] [Related]
4. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
[TBL] [Abstract][Full Text] [Related]
5. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes.
Pal P; Fox JM; Hawman DW; Huang YJ; Messaoudi I; Kreklywich C; Denton M; Legasse AW; Smith PP; Johnson S; Axthelm MK; Vanlandingham DL; Streblow DN; Higgs S; Morrison TE; Diamond MS
J Virol; 2014 Aug; 88(15):8213-26. PubMed ID: 24829346
[TBL] [Abstract][Full Text] [Related]
6. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.
Fong RH; Banik SS; Mattia K; Barnes T; Tucker D; Liss N; Lu K; Selvarajah S; Srinivasan S; Mabila M; Miller A; Muench MO; Michault A; Rucker JB; Paes C; Simmons G; Kahle KM; Doranz BJ
J Virol; 2014 Dec; 88(24):14364-79. PubMed ID: 25275138
[TBL] [Abstract][Full Text] [Related]
7. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.
Tumkosit U; Siripanyaphinyo U; Takeda N; Tsuji M; Maeda Y; Ruchusatsawat K; Shioda T; Mizushima H; Chetanachan P; Wongjaroen P; Matsuura Y; Tatsumi M; Tanaka A
J Virol; 2020 Sep; 94(19):. PubMed ID: 32699087
[TBL] [Abstract][Full Text] [Related]
8. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development.
Kam YW; Lee WW; Simarmata D; Le Grand R; Tolou H; Merits A; Roques P; Ng LF
PLoS One; 2014; 9(4):e95647. PubMed ID: 24755730
[TBL] [Abstract][Full Text] [Related]
9. Chikungunya Virus Exposure Partially Cross-Protects against Mayaro Virus Infection in Mice.
Fumagalli MJ; de Souza WM; de Castro-Jorge LA; de Carvalho RVH; Castro ÍA; de Almeida LGN; Consonni SR; Zamboni DS; Figueiredo LTM
J Virol; 2021 Nov; 95(23):e0112221. PubMed ID: 34549980
[TBL] [Abstract][Full Text] [Related]
10. Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses.
Malonis RJ; Earnest JT; Kim AS; Angeliadis M; Holtsberg FW; Aman MJ; Jangra RK; Chandran K; Daily JP; Diamond MS; Kielian M; Lai JR
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34507983
[TBL] [Abstract][Full Text] [Related]
11. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.
Selvarajah S; Sexton NR; Kahle KM; Fong RH; Mattia KA; Gardner J; Lu K; Liss NM; Salvador B; Tucker DF; Barnes T; Mabila M; Zhou X; Rossini G; Rucker JB; Sanders DA; Suhrbier A; Sambri V; Michault A; Muench MO; Doranz BJ; Simmons G
PLoS Negl Trop Dis; 2013; 7(9):e2423. PubMed ID: 24069479
[TBL] [Abstract][Full Text] [Related]
12. Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice.
Piper A; Ribeiro M; Smith KM; Briggs CM; Huitt E; Nanda K; Spears CJ; Quiles M; Cullen J; Thomas ME; Brown DT; Hernandez R
J Virol; 2013 Jun; 87(12):6748-57. PubMed ID: 23552427
[TBL] [Abstract][Full Text] [Related]
13. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.
Mallilankaraman K; Shedlock DJ; Bao H; Kawalekar OU; Fagone P; Ramanathan AA; Ferraro B; Stabenow J; Vijayachari P; Sundaram SG; Muruganandam N; Sarangan G; Srikanth P; Khan AS; Lewis MG; Kim JJ; Sardesai NY; Muthumani K; Weiner DB
PLoS Negl Trop Dis; 2011 Jan; 5(1):e928. PubMed ID: 21264351
[TBL] [Abstract][Full Text] [Related]
14. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
[TBL] [Abstract][Full Text] [Related]
15. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity.
Weger-Lucarelli J; Aliota MT; Wlodarchak N; Kamlangdee A; Swanson R; Osorio JE
J Virol; 2015 Dec; 90(5):2418-33. PubMed ID: 26676771
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-linked immunosorbent assay using recombinant envelope protein 2 antigen for diagnosis of Chikungunya virus.
Fumagalli MJ; de Souza WM; Espósito DLA; Silva A; Romeiro MF; Martinez EZ; da Fonseca BAL; Figueiredo LTM
Virol J; 2018 Jul; 15(1):112. PubMed ID: 30041676
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence.
Hawman DW; Fox JM; Ashbrook AW; May NA; Schroeder KMS; Torres RM; Crowe JE; Dermody TS; Diamond MS; Morrison TE
Cell Rep; 2016 Aug; 16(5):1326-1338. PubMed ID: 27452455
[TBL] [Abstract][Full Text] [Related]
18. Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation.
Rangel MV; McAllister N; Dancel-Manning K; Noval MG; Silva LA; Stapleford KA
J Virol; 2022 Feb; 96(4):e0158621. PubMed ID: 34935436
[TBL] [Abstract][Full Text] [Related]
19. Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection.
Kishishita N; Takeda N; Anuegoonpipat A; Anantapreecha S
J Clin Microbiol; 2013 May; 51(5):1389-95. PubMed ID: 23408687
[TBL] [Abstract][Full Text] [Related]
20. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
Kam YW; Lum FM; Teo TH; Lee WW; Simarmata D; Harjanto S; Chua CL; Chan YF; Wee JK; Chow A; Lin RT; Leo YS; Le Grand R; Sam IC; Tong JC; Roques P; Wiesmüller KH; Rénia L; Rötzschke O; Ng LF
EMBO Mol Med; 2012 Apr; 4(4):330-43. PubMed ID: 22389221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]